Yellow Fever Clinical Presentation
- Author: Mary T Busowski, MD; Chief Editor: Mark R Wallace, MD, FACP, FIDSA more...
To arrive at a diagnosis, consider the patient's clinical features and his or her places and dates of travel, including the epidemiologic history of the places visited, immunizations, and activities.
After an incubation period of 3-6 days, most individuals with yellow fever have a mild, self-limiting illness consisting of fever, headache, myalgia, and malaise. More serious illness develops in 15% of cases and presents with the abrupt onset of general malaise, fever, chills, headache, lower back pain, nausea, and dizziness. Physical findings include pulse-fever dissociation (Faget sign), conjunctival injection, and facial flushing.
Significant laboratory findings usually include leukopenia with relative neutropenia. Transaminase levels may rise 48-72 hours after initial symptoms appear. This is followed by a period of remission, with normalization of symptoms and temperature for up to 24 hours. The patient may then either recover or progress to fatal illness (up to half of cases).
Remission followed by the return of symptoms is classified as the period of intoxication. Viremia is reduced, and humoral-mediated reactions are responsible for marked physical illness. This stage is marked by fever, vomiting, abdominal pain, renal failure, and hemorrhage. Petechiae, ecchymoses, epistaxis, and bleeding from gums and venipuncture sites can progress to melena, hematemesis, and metrorrhagia.
Jaundice worsens as the levels of transaminases increase, with serum aspartate aminotransferase (AST) levels typically higher than those of alanine aminotransferase (ALT) owing to direct viral injury to skeletal muscle tissue and myocardium. Progressive liver involvement and humoral-mediated responses can lead to consumption coagulopathy. Prolonged clotting and prothrombin times and reduced levels of fibrinogen and clotting factors II, V, VII, VIII, IX, X occur; also, fibrin split products appear.
Hepatorenal disease carries a mortality rate of 20%-50%; with death occurring 7-10 days after onset of symptoms. The terminal phase is marked by delirium, stupor, and coma due to cerebral edema and microscopic perivascular hemorrhage.
Physical examination findings for yellow fever include fever, relative bradycardia for the degree of fever (Faget sign), conjunctival injection, and skin flushing.
Other physical findings, such as scleral icterus, jaundice, epigastric tenderness, and hepatomegaly, develop as disease progresses. Early appearance of jaundice indicates a poor prognosis.
Disseminated intravascular coagulation (DIC), induced by liver dysfunction, leads to consumption of platelets and clotting factors. This process clinically presents as a combination of a bleeding diathesis and organ ischemia secondary to fibrin deposition throughout the microcirculation. Petechiae, purpura, mucosal bleeding, and gastrointestinal bleeding (gross or hemoccult) will often be apparent.
Ischemia primarily affects the kidneys and central nervous system leading to altered mental status and/or signs of volume overload (jugular venous distension, presence of rales, and S3 gallop, or edema).
In late stages of disease, shock and multiorgan dysfunction syndrome (MODS) dominate the clinical picture. These septic patients present with tachycardia, hypothermia or hyperthermia, and hypotension. Individuals who are severely hypoperfused appear mottled and cyanotic. They are also often obtunded.
Tachypnea and hypoxia with impending respiratory failure may develop as a consequence of sepsis and acute respiratory distress syndrome (ARDS).
Cleri DJ, Ricketti AJ, Porwancher RB, Ramos-Bonner LS, Vernaleo JR. Viral hemorrhagic fevers: current status of endemic disease and strategies for control. Infect Dis Clin North Am. 2006 Jun. 20(2):359-93, x. [Medline].
Quaresma JA, Pagliari C, Medeiros DB, Duarte MI, Vasconcelos PF. Immunity and immune response, pathology and pathologic changes: progress and challenges in the immunopathology of yellow fever. Rev Med Virol. 2013 Sep. 23(5):305-18. [Medline].
Barnett ED, Wilder-Smith A, Wilson ME. Yellow fever vaccines and international travelers. Expert Rev Vaccines. 2008 Jul. 7(5):579-87. [Medline].
Bob Arnebeck. A Short History of Yellow Fever in the US. Available at http://www.geocities.com/bobarnebeck/history.html. Accessed: November 11, 2008.
Kean BH, Dahlby T. Coming of age in Panama. One Doctor's Adventures Among the Famous and Infamous from the Jungles of Panama to a Park Avenue Practice. New York, NY: Ballantine Books; 1990. Ch 2.
Bryan CS, Moss SW, Kahn RJ. Yellow fever in the Americas. Infect Dis Clin North Am. 2004. 18:275-279.
Roukens AH, Visser LG. Yellow fever vaccine: past, present and future. Expert Opin Biol Ther. 2008 Nov. 8(11):1787-95. [Medline].
Bhatiasevi A, Moen C. More funding urged for yellow fever vaccine stockpile. WHO News Releases 2009. Available at http://www.who.int/mediacentre/news/releases/2009/yellow_fever_vaccine_20090526/en/index.html. Accessed: May 31, 2009.
Tsai TF, Vaughn DW, Solomon T. Flaviviruses. Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia, Pennsylvania: Elsevier, Inc.; 2005. Vol 2: Ch 149; 1926-9.
World Health Organization. Yellow fever factsheet (revised in December 2009). Weekly Epidemiological Record. Jan 2010.
Barrett AD, Higgs S. Yellow fever: A disease that has yet to be conquered. Annu Rev Entomol. 2007. 52:209-229.
Monath TP. Treatment of yellow fever. Antiviral Res. 2008 Apr. 78(1):116-24. [Medline].
Centers for Disease Control and Prevention. Fatal Yellow Fever in a Traveler Returning from Venezula, 1999. CDC. Apr 14 2000. 49(14):303-5. [Full Text].
Darsie RF, Ward RA. Gainesville FL. Identification and Geographical Distribution of the Mosquitoes of North America. University of Florida Press; 2005.
Morens DM, Fauci AS. Dengue and hemorrhagic fever: a potential threat to public health in the United States. JAMA. 2008 Jan 9. 299(2):214-6. [Medline].
Kim DY, Guzman H, Bueno R Jr, et al. Characterization of Culex Flavivirus (Flaviviridae) strains isolated from mosquitoes in the United States and Trinidad. Virology. 2009 Mar 30. 386(1):154-9. [Medline].
Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis. 2007 Mar 15. 44(6):850-6. [Medline].
World Health Organization. Media centre fact sheets: Yellow fever. Updated December 2001. World Health Organization. Available at http://www.who.int/mediacentre/factsheets/fs100/en/. Accessed: May 13, 2009.
Centers for Disease Control and Prevention. Traveler’s Health. CDC. Available at http://wwwnc.cdc.gov/travel. Accessed: Aug 16 2011.
World Health Organization. WHO position paper: Yellow fever vaccine. Geneva, Switzerland: Oct 2003. Weekly Epidemiological Record; [Full Text].
World Health Organization. Update on progress controlling yellow fever in Africa, 2004-2008. Geneva, Switzerland: Dec 2008. Weekly Epidemiological Record;
Receveur MC, Bruyand M, Pistone T, Malvy D. Yellow fever vaccination: Update on rare and severe adverse effects. Médecine et Maladies Infectieuses. 2009. 39:239-241.
Patel D, Simons H. Yellow fever vaccination: Is one dose always enough?. Travel Med Infect Dis. 2013 Sep 5. [Medline].
Staples JE, Bocchini JA Jr, Rubin L, Fischer M. Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015 Jun 19. 64 (23):647-50. [Medline]. [Full Text].
World Health Organization. Weekly Epidemiological Record. WHO. May 17 2013;88:208-10. Available at http://www.who.int/wer/2013/wer8820.pdf. Accessed: May 29 2013.
Bruyand M, Receveur MC, Pistone T, Verdiere CH, Thiebaut R, Malvy D. [Yellow fever vaccination in non-immunocompetent patients]. Med Mal Infect. 2008 Oct. 38(10):524-32. [Medline].
Barber J. Yellow Fever Vaccination: No Booster Needed for Immunity. Medscape Medical News. May 20 2013. Available at http://www.medscape.com/viewarticle/804480. Accessed: May 29 2013.
Hill DR. Mapping the risk of yellow Fever infection. Curr Infect Dis Rep. 2012 Jun. 14(3):246-55. [Medline].
Paessler S, Walker DH. Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol. 2013 Jan 24. 8:411-40. [Medline].